Sadakatsu Ikeda

List of Publications by Year
in descending order

33	1,264	623734	434195
papers	citations	14 h-index	31 g-index

34	34	34	2396
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncology, 2022, 124, 105666.	1.5	2
2	Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study. PLoS ONE, 2022, 17, e0266112.	2.5	13
3	Primary pulmonary choriocarcinoma with a genomic sequence. Pathology International, 2022, 72, 141-143.	1.3	6
4	First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. Cancer, 2022, , .	4.1	6
5	Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.. Journal of Clinical Oncology, 2022, 40, 3131-3131.	1.6	1
6	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.2	49
7	ASO Author Reflections: Impact of Liquid Biopsy Using Plasma Cell-Free DNA in Solid Tumors in Japan. Annals of Surgical Oncology, 2021, 28, 8506-8507.	1.5	2
8	KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. Oncologist, 2021, 26, e530-e536.	3.7	9
9	Estimating copy number using next-generation sequencing to determine ERBB2 amplification status. Medical Oncology, 2021, 38, 36.	2.5	14
10	A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study). Annals of Surgical Oncology, 2021, 28, 8497-8505.	1.5	8
11	Basaloid Squamous Cell Carcinoma of the Uterine Cervix: Report of a Case With Molecular Analysis. International Journal of Surgical Pathology, 2021, 29, 770-774.	0.8	2
12	Treatment of advanced lung cancer based on genomic profiling using liquid biopsy (plasma): A review of three cases. Thoracic Cancer, 2021, 12, 2508-2512.	1.9	2
13	Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers. Current Oncology, 2021, 28, 3717-3728.	2.2	8
14	METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society. Japanese Journal of Lung Cancer, 2021, 61, 361-370.	0.1	3
15	The clinical utility of comprehensive genomic profiling for recurrent / metastatic head and neck cancer. Japanese Journal of Head and Neck Cancer, 2021, 47, 359-365.	0.1	0
16	Multiplex geneâ€panel testing for lung cancer patients. Pathology International, 2020, 70, 921-931.	1.3	29
17	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. OncoImmunology, 2020, 9, 1708065.	4.6	41
18	A Case Report of a Non-small-cell Lung Cancer Patient Who Was EGFR-negative on a Conventional Test but Was Discovered to Have an EGFR Uncommon Mutation on Comprehensive Genomic Profiling and Responded to Afatinib. Japanese Journal of Lung Cancer, 2020, 60, 429-433.	0.1	2

#	Article	IF	Citations
19	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clinical Cancer Research, 2019, 25, 6107-6118.	7.0	54
20	Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biology and Therapy, 2019, 20, 219-226.	3.4	30
21	Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types.. Journal of Clinical Oncology, 2019, 37, 3046-3046.	1.6	0
22	Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2018, 17, 1114-1122.	4.1	47
23	The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. Molecular Cancer Therapeutics, 2018, 17, 297-305.	4.1	34
24	MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. Journal of Hematology and Oncology, 2018, 11, 76.	17.0	42
25	Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.. Journal of Clinical Oncology, 2018, 36, TPS6094-TPS6094.	1.6	5
26	JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease. JAMA Dermatology, 2017, 153, 449.	4.1	10
27	Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Research, 2017, 77, 5419-5427.	0.9	92
28	The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Molecular Cancer, 2017, 16, 149.	19.2	338
29	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19â€¯784 Diverse Solid Tumors. JAMA Oncology, 2016, 2, 1565.	7.1	195
30	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. Npj Genomic Medicine, 2016, 1, .	3.8	103
31	Single Agent and Synergistic Activity of the â€œFirst-in-Classâ€•Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2016, 15, 2553-2562.	4.1	50
32	Molecular landscape of prostate cancer: Implications for current clinical trials. Cancer Treatment Reviews, 2015, 41, 761-766.	7.7	53
33	Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. Cancer Treatment Reviews, 2015, 41, 699-706.	7.7	14